Company Overview
Divi's Laboratories Limited, a leading Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients, reported strong financial performance for FY 2025-26 with significant growth across key metrics.
Financial Performance Highlights
The company reported standalone revenue from operations of ₹10,388 crores, representing a 13% increase from ₹9,198 crores in FY25. Profit after tax grew 18% to ₹2,607 crores (FY25: ₹2,209 crores), while profit before tax stood at ₹3,436 crores. Earnings per share increased to ₹98.19 from ₹83.20 in the previous year. The Board recommended a final dividend of ₹30 per share (1,500% on face value of ₹2 each), subject to shareholder approval at the upcoming AGM.
Operational and Geographic Performance
Export revenue constituted 89% of total revenue, with Europe being the largest market contributing ₹6,311 crores (60.82% of total revenue). North America contributed 13.10% (₹1,360 crores), India 11.06% (₹1,147 crores), Asia 10.40% (₹1,079 crores), and rest of world 4.62% (₹479 crores). The company maintained strong business segments with custom synthesis contributing more than half of revenues as a key growth driver.
Capital Expenditure and Expansion
The company invested over ₹15 billion across its manufacturing network, with capital work-in-progress standing at ₹2,113 crores (FY25: ₹1,022 crores). Property, plant and equipment capitalized during the year amounted to ₹1,544 crores. Unit 3 at Kakinada became operational from January 1, 2025, enhancing backward integration capabilities across its three manufacturing facilities in Telangana and Andhra Pradesh.
ESG and Sustainability Achievements
Divi's Laboratories demonstrated strong ESG performance with energy conservation of ~8,290 GJ, water conservation of ~159,500 KL, reduction of ~46 MT plastic packaging waste, and GHG emissions reduction of ~13,500 TCO2e. The company achieved 42.50 million safe man-hours and provided ~22 hours of EHS training per employee, with a CSR commitment of ~₹50 crores.
Management and Corporate Governance
Dr. Kiran S. Divi serves as Whole-time Director and Chief Executive Officer with remuneration of ₹34.84 crores for FY26 and holds 5.4 crore equity shares. He was re-appointed for a 5-year term commencing April 1, 2025. The Board comprises 10 directors (5 executive, 5 non-executive independent) with 20% women directors and 50% independent directors, maintaining 100% average board meeting attendance.
Regulatory Compliance and Challenges
The company successfully underwent US FDA general cGMP inspection at Unit 1, Choutuppal, and maintains 41 Drug Master Files with US FDA among other regulatory certifications. The implementation of new labor codes resulted in an exceptional employee benefits expense of ₹74 crores affecting gratuity obligations. Contingent liabilities include disputed tax and duty demands of ₹8 crores and a GST show cause notice of ₹82 crores stayed by High Court.
AGM and Forward Outlook
The 36th Annual General Meeting is scheduled for August 10, 2026, through video conferencing, with key agenda items including adoption of financial statements, dividend declaration, and director re-appointments. The company's forward-looking statements acknowledge risks including changes in economic conditions, government regulations, manufacturing outcomes, market dynamics, currency fluctuations, and geopolitical issues that may impact future performance.